CompletedNCT00506935
GVG or placebo for methamphetamine dependence
About this title
Read the official source — NCT00506935Medication studyAges 18–55United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Los AngelesSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateJuly 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 17
- Sponsor
- Baylor College of Medicine
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00506935
- Official title
Show the full official title
Phase 1 Study of Vigabatrin (GVG) for Methamphetamine Dependence
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Los Angeles
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Baylor College of Medicine, a university.
Did this study involve medication?
Yes. The study involved medication, including GVG and placebo.
Who was this study for?
Listed age limits: 18 years to 55 years.
